For Healthcare Professionals

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

clipboard-pencil

About the study

To assess longitudinal changes in allele frequency of ESR1 mutation in plasma in patients treated with Fulvestrant plus palbociclib compared to tamoxifen plus palbociclib
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

    EXCLUSION CRITERIA

      pin location

      Study Locations

      Enter your ZIP code/Postal code/PIN code to locate study sites near you:

      How to Apply


      Contact the study center to learn if this study is a good match for you.
      Phone iconCall 412-641-2588Email iconEmail Study Center

      Study’s details


      Contition

      Metastatic Breast Cancer

      Age

      18+

      Phase

      Early Phase 1

      Participants needed

      7

      Est. Completion Date

      Oct 2021

      Treatment type

      Interventional


      Sponsor

      University of Pittsburgh

      ClinicalTrials.gov identifier

      NCT02913430

      Study number

      I4D-MC-JTJH

      Understanding Clinical Trials


      Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
      Vector

      Interested?

      Sign up to save your favorites, 
      receive newsletters, resources, and alerts 
      about clinical trials related to your conditions of interest.